Get the Stockscreener App
20.55
2.14%
-0.45
After Hours:
20.51
-0.04
-0.19%
Intellia Therapeutics Inc stock is traded at $20.55, with a volume of 1.08M.
It is down -2.14% in the last 24 hours and down -8.42% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$21.00
Open:
$20.95
24h Volume:
1.08M
Relative Volume:
0.76
Market Cap:
$2.09B
Revenue:
$52.60M
Net Income/Loss:
$-485.50M
P/E Ratio:
-3.7637
EPS:
-5.46
Net Cash Flow:
$-418.08M
1W Performance:
-4.24%
1M Performance:
-8.42%
6M Performance:
-25.30%
1Y Performance:
-35.01%
1-Day Range:
$20.37
$21.39
1-Week Range:
$20.23
$21.87
52-Week Range:
$19.21
$34.87
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk - The Motley Fool
Scientech Research LLC Acquires 26,884 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Intellia: Exciting Promise Of A First In Vivo Gene Therapy Makes Bull Case (NASDAQ:NTLA) - Seeking Alpha
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by American Century Companies Inc. - MarketBeat
Benjamin F. Edwards & Company Inc. Acquires 60,052 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
XTX Topco Ltd Raises Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
(NTLA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Seven Eight Capital LP Acquires New Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Rating Reiterated by Royal Bank of Canada - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Trading 6.8% Higher - MarketBeat
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Press Release Service: Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex PharmaceuticalsResearchAndMarkets.comC - CRISPR Medicine News
Federated Hermes Inc. Has $51.49 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - GlobeNewswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - StockTitan
Intellia Therapeutics (NASDAQ:NTLA) PT Lowered to $64.00 - MarketBeat
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts - Benzinga
Genome Engineering Market 2024-2031 in depth Size Growth - openPR
Intellia Therapeutics (NASDAQ:NTLA) Hits New 12-Month Low at $19.31 - MarketBeat
Intellia stock touches 52-week low at $19.36 amid biotech slump - Investing.com
Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82% - GlobeNewswire Inc.
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate - Simply Wall St
Intellia Therapeutics Enters Oversold Territory (NTLA) - Nasdaq
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Cathie Wood's ARK ETF focuses on Intellia, Recursion stock in latest trades By Investing.com - Investing.com South Africa
Cathie Wood's ARK ETF focuses on Intellia, Recursion stock in latest trades - Investing.com
Cathie Wood's ARK ETF focuses on Intellia, Recursion stock in latest trades - Investing.com Australia
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $61.58 Average PT from Analysts - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 3.6% - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Takes $294,000 Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Hennion & Walsh Asset Management Inc. Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Chevy Chase Trust Holdings LLC Lowers Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Hereditary Angioedema Treatment Market 2032: FDA Approvals, - openPR
BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2 - Yahoo Finance UK
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Sumitomo Mitsui Trust Holdings Inc. - MarketBeat
NTLA (Intellia Therapeutics) Enterprise Value : $1,691.62 Mil (As of Aug. 14, 2024) - GuruFocus.com
Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements - Yahoo Finance
JPMorgan Chase & Co. Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $55.00 - Defense World
3 High-Risk Undervalued Stocks for Aggressive Investors Targeting 35%+ Upside - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $55.00 - MarketBeat
Brookline Capital Management Research Analysts Decrease Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Royal Bank of Canada Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $54.00 - Defense World
Intellia Therapeutics, Inc. to Post FY2025 Earnings of ($4.40) Per Share, Chardan Capital Forecasts (NASDAQ:NTLA) - Defense World
Phase 3 trial of NTLA-2002, gene-editing therapy, possible in 2024 - Angioedema News Today
Comerica Bank Increases Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Brookline Capital Management Comments on Intellia Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:NTLA) - Defense World
Brokers Offer Predictions for Intellia Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:NTLA) - Defense World
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):